Birgitta Versluijs

143 Outcome predictors in Allo-LS in children In Figure 2 the adjusted Allo-LS free survival according to therapy response is shown (75% vs 4%, p < 0.001) as well as the curves according to GvHD treatment (48% vs 0%, p < 0.001), ICU admission (57% vs 23%, p = 0.003) and RV presence (65% vs 20%, p = 0.004). Figure 3 shows the cumulative incidence of NRM according to therapy response (83% vs 17%, p < 0.001). FIGURE 2. Allo-LS free survival according to (a) therapy response, (b) GVHD treatment prior to Allo-LS, (c) ICU admission for mechanical ventilation, (d) presence of RV at time of Allo- LS. Allo-LS, Alloimmune mediated lung syndrome 74.9% (60%−93%) 4.17% (0.61%−28%) p<0.001** 0.00 0.25 0.50 0.75 1.00 0 300 600 900 Time afterAllo−LSonset Allo−LS free survival a a Responded to therapy Therapy failed 29 25 22 20 24 3 1 1 − − Number at risk 48.2% (36%−65%) p<0.001** 0.00 0.25 0.50 0.75 1.00 0 300 600 900 TimeafterAllo−LSonset Allo−LS free survival a a NoGvHD treatment GvHD treatment 47 27 23 21 6 1 0 0 − − Numberat risk 57.3% (42%−78%) 22.7% (11%−49%) p=0.003** 0.00 0.25 0.50 0.75 1.00 0 300 600 900 Time afterAllo−LSonset Allo−LS free survival a a No ICUadmission ICU admission 31 21 17 15 22 7 6 6 − − Number at risk 20% (8.3%−48%) 64.9% (48%−88%) p=0.004** 0.00 0.25 0.50 0.75 1.00 0 300 600 900 TimeafterAllo−LSonset Allo−LS free survival a a NoRV present RV present 20 5 3 3 23 16 15 15 − − Numberat risk 48.2% (36-65%) 8 A B C D 74.9% (60-93%) 4.17% (0.6-28%) p<0.001** p<0.001** 57.3% (42-78%) 22.7% (11-79%) p=0.003** p=0.004** 64.9% (48-88%) 20% (8.3-48%) 31 21 17 15 22 7 6 6 29 25 22 20 24 3 1 1 47 27 23 21 6 1 0 0 20 5 3 3 22 16 16 16 —  Responded to therapy —  Therapy failed Allo-LS free survival 1,0 0,75 0 Time after Allo-LS onset (days) 0 300 Number at risk 600 900 0,50 0,25 —  No ICU admission —  IC admission Allo-LS free survival 1,0 0,75 0 0,50 0,25 Time after Allo-LS onset (days) 0 300 Number at risk 600 900 1,0 0,75 0 0,50 0,25 1,0 0,75 0 0,50 0,25 —  No GvHD treatment —  GvHD treatment Time after Allo-LS onset (days) 0 300 Number at risk 600 900 Time after Allo-LS onset (days) 0 300 Number at risk 600 900 —  No RV present —  RV present